RE:Biotechs rough yearThe environment for biotechs is pretty horrible at the moment. Naturally, TH is likely to do a deal of some sort in the midst of this debacle for the sector. They have highlighted a debt deal but also noted they need to account for the possible redemption of the convert in a little more than 14 months to make that happen. So, my latest guess is they announce something good in the phase 1a results, sign a Chinese partnership, maybe do one or two other noteworthy things to get favorable attention, implement the ATM to give new shares to institutions who want some exposure to their Sort1+ technology, thereby enough raising money to be able to do a debt deal for further funds needed to fund the cancer trial and maybe the NASH trial too. With $34 currently in the bank, they need a further $23 million to cover off the convert redemption. Will they raise $40 million via the ATM and then a further $75 million via a floating rate debt instrument to fund the cancer trial and perhaps more?